Next Article in Journal / Special Issue
Relevance of the Anti-Inflammatory Properties of Curcumin in Neurodegenerative Diseases and Depression
Previous Article in Journal
Antioxidant Properties of Pyroligneous Acid Obtained by Thermochemical Conversion of Schisandra chinensis Baill
Previous Article in Special Issue
Curcumin and Chronic Kidney Disease (CKD): Major Mode of Action through Stimulating Endogenous Intestinal Alkaline Phosphatase
Open AccessReview

Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment

Laboratory of Molecular and Cellular Biology of Cancer (LBMCC), Hôpital Kirchberg, 9, Rue Edward Steichen, Luxembourg L-2540, Luxembourg
Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
Author to whom correspondence should be addressed.
Molecules 2014, 19(12), 20839-20863;
Received: 9 October 2014 / Revised: 26 November 2014 / Accepted: 27 November 2014 / Published: 12 December 2014
(This article belongs to the Special Issue Curcumin, Inflammation, and Chronic Diseases: How are They Linked?)
Cancer is a multifactorial disease that requires treatments able to target multiple intracellular components and signaling pathways. The natural compound, curcumin, was already described as a promising anticancer agent due to its multipotent properties and huge amount of molecular targets in vitro. Its translation to the clinic is, however, limited by its reduced solubility and bioavailability in patients. In order to overcome these pharmacokinetic deficits of curcumin, several strategies, such as the design of synthetic analogs, the combination with specific adjuvants or nano-formulations, have been developed. By taking into account the risk-benefit profile of drug combinations, as well as the knowledge about curcumin’s structure-activity relationship, a new concept for the combination of curcumin with scaffolds from different natural products or components has emerged. The concept of a hybrid curcumin molecule is based on the incorporation or combination of curcumin with specific antibodies, adjuvants or other natural products already used or not in conventional chemotherapy, in one single molecule. The high diversity of such conjugations enhances the selectivity and inherent biological activities and properties, as well as the efficacy of the parental compound, with particular emphasis on improving the efficacy of curcumin for future clinical treatments. View Full-Text
Keywords: curcumin; hybrid molecules; cancer; bioavailability curcumin; hybrid molecules; cancer; bioavailability
Show Figures

Figure 1

MDPI and ACS Style

Teiten, M.-H.; Dicato, M.; Diederich, M. Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment. Molecules 2014, 19, 20839-20863.

AMA Style

Teiten M-H, Dicato M, Diederich M. Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment. Molecules. 2014; 19(12):20839-20863.

Chicago/Turabian Style

Teiten, Marie-Hélène; Dicato, Mario; Diederich, Marc. 2014. "Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment" Molecules 19, no. 12: 20839-20863.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop